Skip to main content
Premium Trial:

Request an Annual Quote

Genewiz to Acquire Beckman Coulter's Genomic Services Business

NEW YORK (GenomeWeb) – Genomics service provider Genewiz said today that it has agreed to acquire Beckman Coulter's genomic services business.

The deal's financial terms were not disclosed. It has been approved by both boards and will close immediately, Genewiz added.

Beckman Coulter's genomic service business provides sequencing services — including comprehensive Sanger sequencing, next-generation sequencing, bioinformatics, and CLIA and clinical services — to healthcare businesses, academia, and government institutions. Genewiz chairman and CEO Steve Sun praised the deal in a statement today, saying the acquisition "is an ideal fit with Genewiz's global strategy and expansion plans."

Beckman Coulter's genomics services business has proven its leadership role in the market, Sun added, and its experts "have built an efficient workflow that allows for the delivery of quality and timely results to its customers. The integration of these two businesses will allow for an increased level of service and value to customers worldwide." 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.